Monoclonal antibodies that target checkpoint molecules on either T cells or on tumor cells (termed checkpoint inhibitors, see table Some Immunotherapeutic Agents in Clinical Use) are used to prevent downregulation of antitumor immune responses and effectively treat some heretofore resistant cancers and boost the antitumor response.